Emanuela Palmerini

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Alessandro Gronchi, Aisha Miah, Angelo Paolo Dei Tos et al. · Annals of Oncology · 2021 · 989 citations · Full text

Medicine, Oncology, Surgery +14

Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

Paolo G. Casali, Jean‐Yves Blay, N. Abecassis et al. · Annals of Oncology · 2021 · 563 citations · Full text

Medicine, Oncology, Surgery +12

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 489 citations

Medicine, Oncology, Surgery +17

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

William D. Tap, Hans Gelderblom, Emanuela Palmerini et al. · The Lancet · 2019 · 474 citations · Full text

Medicine, Oncology, Pharmacology +5

Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Sandra J. Strauss, Anna Maria Frezza, N. Abecassis et al. · Annals of Oncology · 2021 · 455 citations · Full text

Medicine, Oncology, Surgery +12